ABBOTT-CITALOPRAM TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

Доступна з:

ABBOTT LABORATORIES, LIMITED

Код атс:

N06AB04

ІПН (Міжнародна Ім'я):

CITALOPRAM

Дозування:

40MG

Фармацевтична форма:

TABLET

Склад:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 40MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

100

Тип рецепту:

Prescription

Терапевтична области:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Огляд продуктів:

Active ingredient group (AIG) number: 0136243002; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2015-12-31

Характеристики продукта

_ _
_Abbott-Citalopram Product Monograph _
_Page 1 of 48_
PRODUCT MONOGRAPH
PR
ABBOTT-CITALOPRAM _ _
Citalopram Tablets USP
10 mg, 20 mg and 40 mg citalopram (as citalopram hydrobromide)
Antidepressant
BGP Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
January 7, 2015
Submission Control No.: 180716
_ _
_Abbott-Citalopram Product Monograph _
_Page 2 of 48 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND STABILITY
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
..........................................................................31
CLINICAL TRIALS
.......................................................................................